157 related articles for article (PubMed ID: 36037125)
21. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China.
He P; Wang JJ; Duan W; Song C; Yang Y; Wu QQ
J Ovarian Res; 2021 Dec; 14(1):169. PubMed ID: 34857005
[TBL] [Abstract][Full Text] [Related]
22. External Validation of the Assessment of Different NEoplasias in the adneXa Model Performance in Evaluating the Risk of Ovarian Carcinoma Before Surgery in China: A Tertiary Center Study.
Zhang Y; Zhao Y; Feng L
J Ultrasound Med; 2022 Sep; 41(9):2333-2342. PubMed ID: 34918371
[TBL] [Abstract][Full Text] [Related]
23. Comparison of International Ovarian Tumor Analysis ADNEX model and Ovarian-Adnexal Reporting and Data System with final histological diagnosis in adnexal masses: a retrospective study.
Filiz AA; Kahyaoglu S; Atalay CR
Obstet Gynecol Sci; 2024 Jan; 67(1):86-93. PubMed ID: 37822234
[TBL] [Abstract][Full Text] [Related]
24. Two-Step Strategy for Optimizing the Preoperative Classification of Adnexal Masses in a University Hospital, Using International Ovarian Tumor Analysis Models: Simple Rules and Assessment of Different NEoplasias in the adneXa Model.
Esquivel Villabona AL; Rodríguez JN; Ayala N; Buriticá C; Gómez AC; Velandia AM; Rodríguez N; Alcázar JL
J Ultrasound Med; 2022 Feb; 41(2):471-482. PubMed ID: 33890698
[TBL] [Abstract][Full Text] [Related]
25. Application of Ultrasound Scores (Subjective Assessment, Simple Rules Risk Assessment, ADNEX Model, O-RADS) to Adnexal Masses of Difficult Classification.
Pelayo M; Sancho-Sauco J; Sánchez-Zurdo J; Perez-Mies B; Abarca-Martínez L; Cancelo-Hidalgo MJ; Sainz-Bueno JA; Alcázar JL; Pelayo-Delgado I
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685323
[TBL] [Abstract][Full Text] [Related]
26. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients With Adnexal Masses.
Qian L; Du Q; Jiang M; Yuan F; Chen H; Feng W
Front Oncol; 2021; 11():673722. PubMed ID: 34141619
[TBL] [Abstract][Full Text] [Related]
28. Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population.
Pascual MA; Vancraeynest L; Timmerman S; Ceusters J; Ledger A; Graupera B; Rodriguez I; Valero B; Landolfo C; Testa AC; Bourne T; Timmerman D; Valentin L; Van Calster B; Froyman W
Ultrasound Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38477179
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.
Xie WT; Wang YQ; Xiang ZS; Du ZS; Huang SX; Chen YJ; Tang LN
J Ovarian Res; 2022 Jan; 15(1):15. PubMed ID: 35067220
[TBL] [Abstract][Full Text] [Related]
30. The ADNEX model to triage adnexal masses: An external validation study and comparison with the IOTA two-step strategy and subjective assessment by an experienced ultrasound operator.
Viora E; Piovano E; Baima Poma C; Cotrino I; Castiglione A; Cavallero C; Sciarrone A; Bastonero S; Iskra L; Zola P
Eur J Obstet Gynecol Reprod Biol; 2020 Apr; 247():207-211. PubMed ID: 32146226
[TBL] [Abstract][Full Text] [Related]
31. Comparison of performance between O-RADS, IOTA simple rules risk assessment and ADNEX model in the discrimination of ovarian Brenner tumors.
Shang J; Lei T; Wu L; Lin M; Xie H
Arch Gynecol Obstet; 2023 Sep; 308(3):961-970. PubMed ID: 37186266
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a symptom-based score in combination with CA125 to predict ovarian malignancy in women with adnexal mass.
Krishnamurthy A; Durairaj J; Subbaiah M
J Egypt Natl Canc Inst; 2022 Feb; 34(1):7. PubMed ID: 35171383
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.
Zheng H; Tie Y; Wang X; Yang Y; Wei X; Zhao X
Medicine (Baltimore); 2019 Feb; 98(7):e14577. PubMed ID: 30762809
[TBL] [Abstract][Full Text] [Related]
34. Validation of IOTA-ADNEX Model in Discriminating Characteristics of Adnexal Masses: A Comparison with Subjective Assessment.
Jeong SY; Park BK; Lee YY; Kim TJ
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604883
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study.
Sayasneh A; Ferrara L; De Cock B; Saso S; Al-Memar M; Johnson S; Kaijser J; Carvalho J; Husicka R; Smith A; Stalder C; Blanco MC; Ettore G; Van Calster B; Timmerman D; Bourne T
Br J Cancer; 2016 Aug; 115(5):542-8. PubMed ID: 27482647
[TBL] [Abstract][Full Text] [Related]
36. External validation of the MR imaging scoring system for the management of adnexal masses.
Ruiz M; Labauge P; Louboutin A; Limot O; Fauconnier A; Huchon C
Eur J Obstet Gynecol Reprod Biol; 2016 Oct; 205():115-9. PubMed ID: 27583370
[TBL] [Abstract][Full Text] [Related]
37. Performance of the IOTA ADNEX Model on Selected Group of Patients with Borderline Ovarian Tumours.
Gaurilcikas A; Gedgaudaite M; Cizauskas A; Atstupenaite V; Paskauskas S; Gaurilcikiene D; Birzietis T; Vaitkiene D; Nadisauskiene RJ
Medicina (Kaunas); 2020 Dec; 56(12):. PubMed ID: 33322438
[No Abstract] [Full Text] [Related]
38. ADNEX risk prediction model for diagnosis of ovarian cancer: systematic review and meta-analysis of external validation studies.
Barreñada L; Ledger A; Dhiman P; Collins G; Wynants L; Verbakel JY; Timmerman D; Valentin L; Van Calster B
BMJ Med; 2024; 3(1):e000817. PubMed ID: 38375077
[TBL] [Abstract][Full Text] [Related]
39. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
[TBL] [Abstract][Full Text] [Related]
40. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
